Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency

BACKGROUND: The experience from clinical trials indicates that anti-Aβ immunotherapy could be effective in early/pre-clinical stages of AD, whereas at the late stages promoting the clearing of Aβ alone may be insufficient to halt the disease progression. At the same time, pathological tau correlates...

Descripción completa

Detalles Bibliográficos
Autores principales: Agadjanyan, Michael G., Zagorski, Karen, Petrushina, Irina, Davtyan, Hayk, Kazarian, Konstantin, Antonenko, Maxim, Davis, Joy, Bon, Charles, Blurton-Jones, Mathew, Cribbs, David H., Ghochikyan, Anahit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418694/
https://www.ncbi.nlm.nih.gov/pubmed/28472993
http://dx.doi.org/10.1186/s13024-017-0172-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418694/
https://www.ncbi.nlm.nih.gov/pubmed/28472993
http://dx.doi.org/10.1186/s13024-017-0172-1

Ejemplares similares